Treatment with lamivudine versus lamivudine and thymosin alpha-1 for e antigen-positive chronic hepatitis B patients: a meta-analysis
Open Access
- 25 May 2009
- journal article
- review article
- Published by Springer Nature in Virology Journal
- Vol. 6 (1) , 63
Abstract
Background: Currently, there is no evidence on the combination of lamivudine and thymosin alpha-1 on chronic hepatitis B patients. The aim of this study was to compare the effect of lamivudine monotherapy with that of lamivudine and thymosin alpha-1 combination therapy for the treatment of hepatitis B e antigen (HBeAg)-positive hepatitis B patients. Results: We searched PUBMED (from 1966 onwards), EMBASE (from 1966), CBMdisk (Chinese Biomedical Database, from 1978), CNKI (National Knowledge Infrastructure, from 1980), the Cochrane Central Register of Controlled Trials and the Cochrane Database of Systematic Reviews. Eight trials (583 patients in total) were identified. The lamivudine and thymosin alpha-1 combination treatment was significantly superior to lamivudine treatment in terms of ALT normalization rate (80.2% vs. 68.8%, P = 0.01), virological response rate (84.7% vs. 74.9%, P = 0.002), and HBeAg seroconversion rate (45.1% vs. 15.2%, P < 0.00001). Conclusion: Among HBeAg-positive patients, thymosin alpha-1 and lamivudine combination therapy may be more effective than lamivudine monotherapy, providing superior rates of biochemical response, virological response, and HBeAg seroconversion.Keywords
This publication has 16 references indexed in Scilit:
- Combination therapy of thymosin alpha-1 and lamivudine for HBeAg positive chronic hepatitis B: A prospective randomized, comparative pilot studyJournal of Gastroenterology and Hepatology, 2008
- Management of chronic hepatitis B virus infection: a new era of disease controlInternal Medicine Journal, 2006
- Hepatitis B virus infection: Current statusThe American Journal of Medicine, 2005
- The efficacy and safety of thymosin alpha‐1 in Japanese patients with chronic hepatitis B; results from a randomized clinical trialJournal of Viral Hepatitis, 2005
- Thymalfasin (thymosin‐alpha 1) therapy in patients with chronic hepatitis BJournal of Gastroenterology and Hepatology, 2004
- Hepatitis B Virus Infection — Natural History and Clinical ConsequencesNew England Journal of Medicine, 2004
- Thymalfasin for the treatment of chronic hepatitis B.Expert Review of Anti-infective Therapy, 2004
- Viral hepatitis BThe Lancet, 2003
- ThymalfasinBioDrugs, 1998
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986